Results 81 to 90 of about 3,492,883 (216)

Traditional Chinese Medicine for lung cancer: Mechanisms, clinical evidence, and future perspectives

Precision Medical Sciences, EarlyView.
Graphical abstract represents the risk factors for lung cancer, TCM efficacy and clinical outcomes to future challenges. Abstract Lung cancer remains a leading cause of global cancer mortality. Despite advances in conventional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, challenges including drug resistance, toxicity ...
Zhangdeng Chen, Liujun Bao
wiley   +1 more source

Management of Treatment Resistant EGFR Inhibitor‐Induced Papulopustular Exanthema With Isotretinoin and Dapsone

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives Epidermal growth factor receptor inhibitors (EGFRi) commonly cause papulopustular exanthemas that may compromise the success of cancer therapy. While tetracyclines are first‐line treatment, data on alternative systemic agents for refractory cases remain limited.
Ishana Dixit, Raquel Ruiz Araujo, Pablo Fernandez‐Peñas   +2 more
wiley   +1 more source

Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer. [PDF]

PLoS ONE, 2013
The use of tyrosine kinase inhibitors (TKIs) against EGFR/c-Met in non-small cell lung cancer (NSCLC) has been shown to be effective in increasing patient progression free survival (PFS), but their efficacy is limited due to the development of resistance
Jason T Fong, Ryan J Jacobs, David N Moravec, Srijayaprakash B Uppada, Gregory M Botting, Marie Nlend, Neelu Puri   +6 more
doaj   +1 more source

Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway

Cells, 2022
Integrin β3 plays a key role in the resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI), but the development of integrin β3 inhibitors has been stalled due to the failure of phase III clinical trials for cancer treatment.
Qi Sun, Zhihua Lu, Yanpeng Zhang, Dong Xue, Huayu Xia, Junjun She, Fanni Li   +6 more
doaj   +1 more source

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells [PDF]

, 2015
Epidermal growth factor receptor (EGFR), member of the human epidermal growth factor receptor (HER) family, plays a critical role in regulating multiple cellular processes including proliferation, differentiation, cell migration and cell survival ...
Cardinali, Beatrice, FUSTAINO, VALENTINA, GIANNINI, Giuseppe, LALLI, CRISTIANA, Papoff, Giuliana, PRESUTTI, DARIO, Ruberti, Giovina, Samperna, Simone, Santini, Simonetta   +8 more
core   +3 more sources

Hyperthermia‐induced cytotoxicity and modulation of PD‐L1 and MHC‐I expression in human non‐small cell lung cancer cell lines

Experimental Physiology, EarlyView.
Abstract Hyperthermia has recently been applied to treat human non‐small cell lung cancer (NSCLC). However, the mechanisms underlying cytotoxic sensitivity of NSCLC cells to hyperthermia are not fully understood. In this study, five NSCLC cell lines with different epidermal growth factor receptor (EGFR), Kirsten rat sarcoma and tumor protein p53 ...
Yun‐Chieh Tu, Wei‐Chen Yeh, Yi‐Wei Fang, Ko‐Hsuan Lo, Lei‐Ni Liang, Xu‐Chen Liu, Chia‐Chi Tsai, Chih‐Cheng Cheng, Meng‐Chieh Lin, Hsin‐Hsien Yu, Bor‐Chyuan Su   +10 more
wiley   +1 more source

The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells

Journal of Experimental & Clinical Cancer Research, 2019
Background/aims A novel paradigm in tumor biology suggests that osteosarcoma (OS) chemo-resistance is driven by osteosarcoma stem cell-like cells (OSCs).
Tian Wang, Dexing Wang, Lian Zhang, Ping Yang, Jing Wang, Qi Liu, Fei Yan, Feng Lin   +7 more
doaj   +1 more source

Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. [PDF]

, 2017
Cross-talk among oncogenic signaling and metabolic pathways may create opportunities for new therapeutic strategies in cancer. Here we show that although acute inhibition of EGFR-driven glucose metabolism induces only minimal cell death, it lowers the ...
A Magi, AM Spence, Anthony Letai, AV Follis, AV Vaseva, BA Tannous, BJ Altman, Brian Higgins, C Tovar, CW Brennan, D Jiang, D Nathanson, DA Nathanson, DA Reardon, David A Nathanson, DR Green, E Cerami, E Strom, E Tasdemir, EH Cheng, EQ Lee, G Lessene, H Dai, H Takanaga, Harley I Kornblum, I Babic, I Vivanco, J Deng, J Gao, J Lee, J Lehár, J Montero, J Pomerantz, Jason T Lee, JC Liu, JE Chipuk, JE Chipuk, JE Chipuk, JIJ Leu, Jonathan E Tsang, JP Kruse, K Masui, L Qu, Laura Gosa, Lisa Ta, M Mihara, M-K Han, MG Vander Heiden, Mitra Dehghan Harati, MJ Lee, Nicholas A Bayley, OD Maddocks, P Nagesh Rao, Paul S Mischel, Peter M Clark, PM Clark, PY Wen, Q Ding, R Haq, RGW Verhaak, RJ DeBerardinis, Steven J Bensinger, TF Cloughesy, Timothy F Cloughesy, Veerle W Daniels, W Blake Gilmore, W Wei, WH Yang, William H Yong, Wilson X Mai, Y Zhang, Y Zhao   +71 more
core   +1 more source

Effect of Ephedra Herb on Erlotinib Resistance in c-Met-Overexpressing Non-Small-Cell Lung Cancer Cell Line, H1993, through Promotion of Endocytosis and Degradation of c-Met

, 2020
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) are used to treat non-small-cell lung cancer (NSCLC), harboring an EGFR-activating mutation. However, acquired resistance to these treatments emerges after a few years. One of
S. Hyuga, M. Hyuga, Y. Amakura, Jinwei Yang, Eiko Mori, T. Hakamatsuka, Y. Goda, H. Odaguchi, T. Hanawa   +8 more
semanticscholar   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source